Skip to main content
NCBI home page
Netherlands Heart Journal logoLink to Netherlands Heart Journal
. 2005 Dec;13(12):452–460.

Hypertrophic cardiomyopathy in daily practice: an introduction on diagnosis, prognosis and treatment

C van der Lee, M J Kofflard, ML Geleijnse, FJ ten Cate
PMCID: PMC2497370  PMID: 25696443

Abstract

Hypertrophic cardiomyopathy (HCM) is a complex, inherited cardiac disease that has been subject to intense investigation since it was first described in 1957. Over the past 40 years, understanding has evolved regarding the diagnosis, prognosis and treatment of HCM. Analyses of HCM populations from nonreferral centres have refined the insights into the natural history and the occurrence of sudden cardiac death, which is the most devastating component of its natural history. Therapeutic strategies are diverse and may vary during the course of the disease. Optimal therapy depends on symptoms, haemodynamic findings and the presence of risk factors for sudden cardiac death. At present, invasive therapy for patients with obstructive HCM and drug-refractory symptoms includes surgery or percutaneous transluminal septal myocardial ablation.

This report summarises the diagnostic criteria, clinical course and therapeutic management of HCM. Attention is also paid to certain issues of special interest in this disease.

Keywords: cardiiomyopathy, myectomy, septal ablation

Full text

PDF
452

Images in this article

453Figure 1
on p.453
453Figure 2
on p.453
456Figure 4
on p.456
457Figure 5
on p.457
457Figure 6
on p.457

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alders Marielle, Jongbloed Roselie, Deelen Wout, van den Wijngaard Arthur, Doevendans Pieter, Ten Cate Folkert, Regitz-Zagrosek Vera, Vosberg Hans Peter, van Langen Irene, Wilde Arthur. The 2373insG mutation in the MYBPC3 gene is a founder mutation, which accounts for nearly one-fourth of the HCM cases in the Netherlands. Eur Heart J. 2003 Oct;24(20):1848–1853. doi: 10.1016/s0195-668x(03)00466-4. [DOI] [PubMed] [Google Scholar]
  2. BROCK R. Functional obstruction of the left ventricle; acquired aortic subvalvar stenosis. Guys Hosp Rep. 1957;106(4):221–238. [PubMed] [Google Scholar]
  3. Charron P., Dubourg O., Desnos M., Bennaceur M., Carrier L., Camproux A. C., Isnard R., Hagege A., Langlard J. M., Bonne G. Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene. Circulation. 1998 Jun 9;97(22):2230–2236. doi: 10.1161/01.cir.97.22.2230. [DOI] [PubMed] [Google Scholar]
  4. Elliott Perry, McKenna William J. Hypertrophic cardiomyopathy. Lancet. 2004 Jun 5;363(9424):1881–1891. doi: 10.1016/S0140-6736(04)16358-7. [DOI] [PubMed] [Google Scholar]
  5. Gomes Aldrin V., Potter James D. Cellular and molecular aspects of familial hypertrophic cardiomyopathy caused by mutations in the cardiac troponin I gene. Mol Cell Biochem. 2004 Aug;263(1-2):99–114. doi: 10.1023/B:MCBI.0000041852.42291.aa. [DOI] [PubMed] [Google Scholar]
  6. Hardarson T., De la Calzada C. S., Curiel R., Goodwin J. F. Prognosis and mortality of hypertrophic obstructive cardiomyopathy. Lancet. 1973 Dec 29;2(7844):1462–1467. doi: 10.1016/s0140-6736(73)92730-x. [DOI] [PubMed] [Google Scholar]
  7. Hughes Siân E., McKenna William J. New insights into the pathology of inherited cardiomyopathy. Heart. 2005 Feb;91(2):257–264. doi: 10.1136/hrt.2004.040337. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Jongbloed Roselie J., Marcelis Carlo L., Doevendans Pieter A., Schmeitz-Mulkens Judith M., Van Dockum Willem G., Geraedts Joep P., Smeets Hubert J. Variable clinical manifestation of a novel missense mutation in the alpha-tropomyosin (TPM1) gene in familial hypertrophic cardiomyopathy. J Am Coll Cardiol. 2003 Mar 19;41(6):981–986. doi: 10.1016/s0735-1097(02)03005-x. [DOI] [PubMed] [Google Scholar]
  9. Klues H. G., Schiffers A., Maron B. J. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol. 1995 Dec;26(7):1699–1708. doi: 10.1016/0735-1097(95)00390-8. [DOI] [PubMed] [Google Scholar]
  10. Koga Y., Itaya K., Toshima H. Prognosis in hypertrophic cardiomyopathy. Am Heart J. 1984 Aug;108(2):351–359. doi: 10.1016/0002-8703(84)90624-0. [DOI] [PubMed] [Google Scholar]
  11. Lemery R., Kleinebenne A., Nihoyannopoulos P., Aber V., Alfonso F., McKenna W. J. Q waves in hypertrophic cardiomyopathy in relation to the distribution and severity of right and left ventricular hypertrophy. J Am Coll Cardiol. 1990 Aug;16(2):368–374. doi: 10.1016/0735-1097(90)90587-f. [DOI] [PubMed] [Google Scholar]
  12. Marian A. J., Roberts R. Recent advances in the molecular genetics of hypertrophic cardiomyopathy. Circulation. 1995 Sep 1;92(5):1336–1347. doi: 10.1161/01.cir.92.5.1336. [DOI] [PubMed] [Google Scholar]
  13. Marian A. J., Salek L., Lutucuta S. Molecular genetics and pathogenesis of hypertrophic cardiomyopathy. Minerva Med. 2001 Dec;92(6):435–451. [PMC free article] [PubMed] [Google Scholar]
  14. Maron B. J., Anan T. J., Roberts W. C. Quantitative analysis of the distribution of cardiac muscle cell disorganization in the left ventricular wall of patients with hypertrophic cardiomyopathy. Circulation. 1981 Apr;63(4):882–894. doi: 10.1161/01.cir.63.4.882. [DOI] [PubMed] [Google Scholar]
  15. Maron B. J., Gardin J. M., Flack J. M., Gidding S. S., Kurosaki T. T., Bild D. E. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation. 1995 Aug 15;92(4):785–789. doi: 10.1161/01.cir.92.4.785. [DOI] [PubMed] [Google Scholar]
  16. Maron B. J., Pelliccia A., Spirito P. Cardiac disease in young trained athletes. Insights into methods for distinguishing athlete's heart from structural heart disease, with particular emphasis on hypertrophic cardiomyopathy. Circulation. 1995 Mar 1;91(5):1596–1601. doi: 10.1161/01.cir.91.5.1596. [DOI] [PubMed] [Google Scholar]
  17. Maron B. J., Wolfson J. K., Ciró E., Spirito P. Relation of electrocardiographic abnormalities and patterns of left ventricular hypertrophy identified by 2-dimensional echocardiography in patients with hypertrophic cardiomyopathy. Am J Cardiol. 1983 Jan 1;51(1):189–194. doi: 10.1016/s0002-9149(83)80034-4. [DOI] [PubMed] [Google Scholar]
  18. Maron Barry J. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002 Mar 13;287(10):1308–1320. doi: 10.1001/jama.287.10.1308. [DOI] [PubMed] [Google Scholar]
  19. McKenna W. J., England D., Doi Y. L., Deanfield J. E., Oakley C., Goodwin J. F. Arrhythmia in hypertrophic cardiomyopathy. I: Influence on prognosis. Br Heart J. 1981 Aug;46(2):168–172. doi: 10.1136/hrt.46.2.168. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Moolman J. C., Corfield V. A., Posen B., Ngumbela K., Seidman C., Brink P. A., Watkins H. Sudden death due to troponin T mutations. J Am Coll Cardiol. 1997 Mar 1;29(3):549–555. doi: 10.1016/s0735-1097(96)00530-x. [DOI] [PubMed] [Google Scholar]
  21. Obeid A. I., Maron B. J. Apical hypertrophic cardiomyopathy developing at a relatively advanced age. Circulation. 2001 Mar 20;103(11):1605–1605. doi: 10.1161/01.cir.103.11.1605. [DOI] [PubMed] [Google Scholar]
  22. Osterop A. P., Kofflard M. J., Sandkuijl L. A., ten Cate F. J., Krams R., Schalekamp M. A., Danser A. H. AT1 receptor A/C1166 polymorphism contributes to cardiac hypertrophy in subjects with hypertrophic cardiomyopathy. Hypertension. 1998 Nov;32(5):825–830. doi: 10.1161/01.hyp.32.5.825. [DOI] [PubMed] [Google Scholar]
  23. Poetter K., Jiang H., Hassanzadeh S., Master S. R., Chang A., Dalakas M. C., Rayment I., Sellers J. R., Fananapazir L., Epstein N. D. Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nat Genet. 1996 May;13(1):63–69. doi: 10.1038/ng0596-63. [DOI] [PubMed] [Google Scholar]
  24. Schwartz K., Carrier L., Guicheney P., Komajda M. Molecular basis of familial cardiomyopathies. Circulation. 1995 Jan 15;91(2):532–540. doi: 10.1161/01.cir.91.2.532. [DOI] [PubMed] [Google Scholar]
  25. Schwartz Ketty, Mercadier Jean-Jacques. Cardiac troponin T and familial hypertrophic cardiomyopathy: an energetic affair. J Clin Invest. 2003 Sep;112(5):652–654. doi: 10.1172/JCI19632. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Shah P. M., Adelman A. G., Wigle E. D., Gobel F. L., Burchell H. B., Hardarson T., Curiel R., De La Calzada C., Oakley C. M., Goodwin J. F. The natural (and unnatural) history of hypertrophic obstructive cardiomyopathy. Circ Res. 1974 Aug;35(2):suppl II–II:195. [PubMed] [Google Scholar]
  27. Sharma S., Elliott P. M., Whyte G., Mahon N., Virdee M. S., Mist B., McKenna W. J. Utility of metabolic exercise testing in distinguishing hypertrophic cardiomyopathy from physiologic left ventricular hypertrophy in athletes. J Am Coll Cardiol. 2000 Sep;36(3):864–870. doi: 10.1016/s0735-1097(00)00816-0. [DOI] [PubMed] [Google Scholar]
  28. Swan D. A., Bell B., Oakley C. M., Goodwin J. Analysis of symptomatic course and prognosis and treatment of hypertrophic obstructive cardiomyopathy. Br Heart J. 1971 Sep;33(5):671–685. doi: 10.1136/hrt.33.5.671. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Van Driest Sara L., Jaeger Michele A., Ommen Steve R., Will Melissa L., Gersh Bernard J., Tajik A. Jamil, Ackerman Michael J. Comprehensive analysis of the beta-myosin heavy chain gene in 389 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004 Aug 4;44(3):602–610. doi: 10.1016/j.jacc.2004.04.039. [DOI] [PubMed] [Google Scholar]
  30. Van Driest Sara L., Vasile Vlad C., Ommen Steve R., Will Melissa L., Tajik A. Jamil, Gersh Bernard J., Ackerman Michael J. Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004 Nov 2;44(9):1903–1910. doi: 10.1016/j.jacc.2004.07.045. [DOI] [PubMed] [Google Scholar]
  31. Varnava A. M., Elliott P. M., Baboonian C., Davison F., Davies M. J., McKenna W. J. Hypertrophic cardiomyopathy: histopathological features of sudden death in cardiac troponin T disease. Circulation. 2001 Sep 18;104(12):1380–1384. doi: 10.1161/hc3701.095952. [DOI] [PubMed] [Google Scholar]
  32. Watkins H., McKenna W. J., Thierfelder L., Suk H. J., Anan R., O'Donoghue A., Spirito P., Matsumori A., Moravec C. S., Seidman J. G. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med. 1995 Apr 20;332(16):1058–1064. doi: 10.1056/NEJM199504203321603. [DOI] [PubMed] [Google Scholar]
  33. Yamaguchi H., Ishimura T., Nishiyama S., Nagasaki F., Nakanishi S., Takatsu F., Nishijo T., Umeda T., Machii K. Hypertrophic nonobstructive cardiomyopathy with giant negative T waves (apical hypertrophy): ventriculographic and echocardiographic features in 30 patients. Am J Cardiol. 1979 Sep;44(3):401–412. doi: 10.1016/0002-9149(79)90388-6. [DOI] [PubMed] [Google Scholar]

Articles from Netherlands Heart Journal are provided here courtesy of Springer

RESOURCES